HRTVasomotor symptomsComplianceBenefitsRisksAims: Women in the West can now expect to live one third of their life in a postmenopausal state, and consequently in a state of estrogen deficiency. This can have a number of consequences, and many women suffer vasomotor symptoms during the climacteric....
The first major trial to look at the cardioprotective effects of hormone replacement therapy (HRT) has provided firm evidence that HRT reduces cardiovascular risk in postmenopausal women. With the results of this trial in hand, physicians will be able to make more informed decisions regarding the ...
The 2 meta-analyses by Humphrey and colleagues and Nelson and colleagues, and much of the medical literature, do not clearly define postmenopausal HRT. Although authors often claim that many observational studies show the benefits of HRT on CAD risk, the data almost completely relate to unopposed...
Objective : To review the literature related to the benefits and risks of postmenopausal hormone replacement therapy (HRT). VA Mckeon - 《Journal of Obstetric Gynecologic & Neonatal Nursing》 被引量: 6发表: 2010年 Hormone replacement therapy: risks and benefits For many women, the menopause is ...
Moderation of the daily dose of HRT: prevention of osteoporosis Introduction and methods: Osteoporosis is the most common bone disease in clinical practice. Between 30% and 50% of postmenopausal women and almost 50% of ... JC Gallagher - 《Maturitas》 被引量: 71发表: 1999年 Moderation of ...
The benefits of hormone replacement therapy (HRT) are well established for the different systemic administration routes used today. Relief from somatic and vasomotor postmenopausal symptoms can be obtained by all recognized forms of HRT. The prophylactic action of peroral and percutaneous administration ...
Commencing hormone replacement therapy (HRT) with conjugated estrogens and medroxyprogesterone cannot be recommended for the secondary prevention of coronary heart disease in postmenopausal women, according to the disappointing results from the recent Heart and Estrogen/progestin Replacement Study (HERS). * ...
To describe the impact of the results of the Women's Health initiative (WHI) on hormone replacement therapy (HRT) discontinuation rates. D... Bestul,B Megan,McCollum,... - 《Pharmacotherapy》 被引量: 42发表: 2004年 Postmenopausal Hormone Therapy Is Not Associated With Risk of All-Cause ...
(PEPI) trial and its study of the effects of HRT on endome- trial histology in postmenopausal women.7 It confirmed that 0.625 mg of CEE daily enhanced the development of endometrial hyperplasia, and that combining CEE with cyclic or continuous medroxyprogesterone acetate MPA protected the ...
Introduction: Currently, progesterone is notably absent from conventional feminizing hormone therapies for transgender women. Anecdotal reports indicate the potential for health advantages following the incorporation of progesterone into treatment regime